Khamaisi Mogher, Balanson Sarit Ella
Internal Medicine D, Rambam Health Care Campus and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Institute of Endocrinology, Diabetes & Metabolism, Rambam Health Care Campus and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Rambam Maimonides Med J. 2017 Jan 30;8(1):e0008. doi: 10.5041/RMMJ.10283.
Long-standing diabetes leads to structural and functional alterations in both the micro- and the macrovasculature. Designing therapies to repair these abnormalities present unique and sophisticated challenges. Vascular endothelial cells are the primary cells damaged by hyperglycemia-induced adverse effects. Vascular stem cells that give rise to endothelial progenitor cells and mesenchymal progenitor cells represent an attractive target for cell therapy for diabetic patients. In this review, we shed light on challenges and recent advances surrounding stem cell therapies for diabetes vascular complications and discuss limitations for their clinical adoption.
长期糖尿病会导致微血管和大血管的结构与功能改变。设计修复这些异常的疗法面临着独特而复杂的挑战。血管内皮细胞是受高血糖诱导的不良影响所损害的主要细胞。产生内皮祖细胞和间充质祖细胞的血管干细胞是糖尿病患者细胞治疗的一个有吸引力的靶点。在本综述中,我们阐明了糖尿病血管并发症干细胞治疗面临的挑战和最新进展,并讨论了其临床应用的局限性。